CSPC Pharmaceutical Group (01093): The Phase III clinical study results of anitumab combined with docetaxel for injection (albumin-bound) (HB1801) for first-line treatment of HER2-positive advanced breast cancer were presented as a preferred oral presentation at the 2026 ESMO Annual Meeting.

Zhihong Financial News APP: CSPC Pharmaceutical Group (01093) announced that the interim analysis results of the Phase III clinical study (study number: HEALER) of anivantamab injection (trade name: Ennitum) co-developed by the Group and Jiangsu Alphamab Biopharmaceuticals Co., Ltd., in combination with docetaxel for injection (albumin-bound) (HB1801) for the first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer, were selected as a Late-breaking Abstract (LBA) at the 2026 European Society for Medical Oncology (ESMO) Annual Congress on October 24, 2026, and were presented in a preferred oral presentation format. At the same time, the study was simultaneously published as an original article in The New England Journal of Medicine (NEJM), making it the first achievement in the field of breast cancer clinical research in mainland China to be published in NEJM.